IQWiG Lifebuoy
Written by: PD Dr. Hans-Peter Dürr | Posted on: | Category: HTA

Can a significant effect remain if we re-analyze it in a subpopulation with lower N?

In the benefit assessment of drugs, it may happen that a benefit must be re-examined in a subpopulation, for example if the approval is restricted to a subpopulation which particularly benefits from the treatment. In these ...

Read More
Written by: Jonathan Alsop, PhD | Posted on: | Category: MAIC

Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer

This recently published MAIC is an interesting one. The authors have clearly gone to great lengths to identify and adjust for potential treatment-effect ...

Read More
Missing data
Written by: Jonathan Alsop, PhD | Posted on: | Category: RWD/RWE

Missing inaction?

Just read a nice Q&A article from Murtuza Bharmal on the increased use of RWD/RWE.

The point he makes on "ensuring minimal missing data" is certainly critical to the external validity of real world ...

Read More
Written by: Jonathan Alsop, PhD | Posted on: | Category: Estimands

Study protocol - you’re either with me or against me!

When it comes to assessing the impact of how well patients (and arguably centres) in a randomised clinical trial follow the protocol, the standard method for some decades has been via the identification of the ‘Per Protocol’ ...

Read More
Categories

By clicking "Accept," you agree to the use of Numerus and third party cookies and other similar technologies to enhance your browsing experience, analyse, and measure your engagement with our content.